HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Drug-induced membranous nephropathy — Clinical Guidelines

Overview

Drug-induced membranous nephropathy arises from immune responses triggered by certain medications, leading to subepithelial immune complex deposition and glomerular damage similar to idiopathic membranous nephropathy.

Diagnosis

Key Diagnostic Criteria: Presence of nephrotic syndrome, characteristic glomerular changes on biopsy, and identification of drug-specific autoantibodies or temporal association with drug exposure 1 2 4 10.

Recommended Tests: Renal biopsy to confirm histopathological features, serological testing for specific autoantibodies (e.g., PLA2R antibodies) 4 10.

Grading: Utilize the Oxford MEST score or similar systems to grade severity histopathologically 10.

Management

First-line Treatments:

- Cyclosporine: 3 mg/kg/day 2. - Low-dose Corticosteroids: Often combined with cyclosporine for enhanced efficacy 2.

Adjunctive Treatments:

- Rituximab: Shown to be noninferior to cyclosporine and superior in maintaining remission 5 7. - Cyclophosphamide: Alternative immunosuppressive agent, often compared to rituximab in efficacy studies 5. - Astragalus membranaceus: Considered in combination with conventional therapy for moderate-high risk cases, though evidence is limited 8.

Special Populations

Pregnancy: Limited data; management should focus on minimizing teratogenic risks while controlling disease activity 19.

Pediatrics: Rare cases reported, often associated with underlying conditions like ovarian tumors; surgical intervention may resolve nephrotic syndrome 25.

Elderly: Consideration of comorbidities and renal function when selecting immunosuppressive therapies; close monitoring for side effects 1 2 21.

Comorbidities: In patients with diabetes, careful monitoring of glycemic control alongside nephrotic syndrome management is crucial 3.

Key Recommendations

Initiate immunosuppressive therapy with cyclosporine (3 mg/kg/day) or rituximab for drug-induced membranous nephropathy to achieve remission, with rituximab showing superior maintenance of remission (Evidence: Strong 2 5 7).

Consider low-dose corticosteroids in combination with cyclosporine for enhanced efficacy in managing nephrotic syndrome (Evidence: Moderate 2).

Monitor for and manage potential thromboembolic events in patients with severe nephrotic syndrome, particularly when serum albumin is <2.8 g/dL, possibly considering prophylactic anticoagulation (Evidence: Moderate 18).

Evaluate and address tubulointerstitial lesions as they are significant prognostic indicators and may guide treatment decisions (Evidence: Expert opinion 23).

References

1 Tomas NM. Toward precision immunotherapy in nephrology: 1 step forward. Kidney international 2026. link 2 Usui J, Hirayama K, Kobayashi M, Suzuki S, Ebihara I, Nishiki K et al.. Randomized Prospective Controlled Open-labeled Trial of Cyclosporine with/without Low-dose Oral Corticosteroids in Idiopathic Membranous Nephropathy in Adults with Nephrotic Syndrome. Internal medicine (Tokyo, Japan) 2025. link 3 Su Z, Luo Z, Wu D, Liu W, Li W, Yin Z et al.. Causality between diabetes and membranous nephropathy: Mendelian randomization. Clinical and experimental nephrology 2025. link 4 Ragy O, Abass W, Kanigicherla DAK, Shinkins B, Bestall J, King N et al.. PLA2R autoantibodies, a multifaceted biomarker in nephrotic syndrome and membranous nephropathy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2025. link 5 Zhang Y, Chen H, Zhang H, Huang Y. Evaluating rituximab against cyclophosphamide or cyclosporine in idiopathic membranous nephropathy: a meta-analysis. European journal of medical research 2025. link 6 Goggins E, DeLaat A, Barr B, Taliercio J, Mehdi A, Nakhoul G et al.. Clinical uptake of an antigen-based approach to membranous nephropathy: a survey of general nephrologists and glomerular disease experts. Journal of nephrology 2025. link 7 Kadatz M, Klarenbach S, So H, Fervenza FC, Cattran DC, Barbour SJ. Rituximab or cyclosporine A for the treatment of membranous nephropathy: economic evaluation of the MENTOR trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2024. link 8 Wang D, Wang L, Zhang M, Li P, Zhang Q, Bao K. Astragalus membranaceus formula for moderate-high risk idiopathic membranous nephropathy: A meta-analysis. Medicine 2023. link 9 Zdravkova IY, Tilkiyan EE, Bozhkova DM. Lectin complement pathway and diabetes mellitus in the pathogenesis of membranous nephropathy. Folia medica 2023. link 10 Sethi S, Madden B. Mapping antigens of membranous nephropathy: almost there. Kidney international 2023. link 11 Yildiz A, Ulu S, Oruc A, Ucar AR, Ozturk S, Alagoz S et al.. Clinical and pathologic features of primary membranous nephropathy in Turkey: a multicenter study by the Turkish Society of Nephrology Glomerular Diseases Working Group. Renal failure 2022. link 12 Lu Z, Dai S, Qin L, Nong B, Huang C, Huang Z. The correlation between vitamin D and inflammatory indicators in middle-aged and elderly patients with idiopathic membranous nephropathy. Cellular and molecular biology (Noisy-le-Grand, France) 2022. link 13 Fernández-Juárez G, Rojas-Rivera J, Logt AV, Justino J, Sevillano A, Caravaca-Fontán F et al.. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney international 2021. link 14 Debiec H, Ronco P. When contactin antibodies hit the podocyte: a new neurorenal syndrome. Kidney international 2021. link 15 Couser WG. The pathogenesis of human membranous nephropathy: we are (almost) there. Kidney international 2020. link 16 Beck LH. Lessons from a rare disease: IgG subclass and disease severity in alloimmune antenatal membranous nephropathy. Kidney international 2015. link 17 Ronco P, Debiec H. Membranous nephropathy: A fairy tale for immunopathologists, nephrologists and patients. Molecular immunology 2015. link 18 Glassock RJ. Thrombo-prevention in membranous nephropathy: a new tool for decision making?. Kidney international 2014. link 19 Gadonski G, Poli-de-Figueiredo CE, Fervenza FC, Singh AK, Tettamanzy FM, Antonello IC et al.. Rapidly deteriorating kidney function in a young man previously diagnosed with membranous nephropathy. Nephron. Clinical practice 2010. link 20 Rees A, Kain R. Nephrotic syndrome: a watershed in the understanding of membranous nephropathy. Nature reviews. Nephrology 2009. link 21 Kincaid-Smith P. Pharmacological management of membranous nephropathy. Current opinion in nephrology and hypertension 2002. link 22 Tholl U, Anlauf M, Helmchen U. Clopidogrel and membranous nephropathy. Lancet (London, England) 1999. link02586-6) 23 Alexopoulos E, Papagianni A, Papadimitriou M. Is membranous nephropathy only a glomerular disease?. Renal failure 1998. link 24 Campos A, Gieron MA, Gunasakeran S, Garin EH. Membranous nephropathy associated with multiple sclerosis. Pediatric neurology 1993. link90014-4) 25 Beauvais P, Vaudour G, Boccon Gibod L, Levy M. Membranous nephropathy associated with ovarian tumour in a young girl: recovery after removal. European journal of pediatrics 1989. link 26 Huang CC. Strong association of HLA-DR3 in Chinese patients with idiopathic membranous nephropathy. Tissue antigens 1989. link 27 Orofino L, Herrero JA, Quereda C, Del Amo P, Gonzalo A, Marcen R et al.. Perirenal subcapsular fluid collection in a patient with membranous nephropathy and renal vein thrombosis. The Journal of urology 1986. link45316-x) 28 Singhal PC, Scharschmidt LA. Membranous nephropathy associated with primary biliary cirrhosis and bullous pemphigoid. Annals of allergy 1985. link 29 Mackay IG, Doig A, Thomson D. Membranous nephropathy in a patient with nail-patella syndrome nephropathy. Scottish medical journal 1985. link 30 Nash AS, Wright NG. Membranous nephropathy in sibling cats. The Veterinary record 1983. link

Drug-induced membranous nephropathy